Не сдохни! Еда в борьбе за жизнь

^{‹‹124››.} Karve A, Hayward RA. Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care. 2010;33(11):2355–9.

^{‹‹125››.} Cardona-Morrell M, Rychetnik L, Morrell SL, Espinel PT, Bauman A. Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health. 2010;10:653.

^{‹‹126››.} Holman H. Chronic disease— the need for a new clinical education. JAMA. 2004;292(9):1057–9.

^{‹‹127››.} Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, D.C.: The National Academies Press, 2001:213. http://www.iom.edu/Reports/2001/Crossing- the-Quality-Chasm-A-New-Health-System-for-the-21st-Century.aspx.

7. Как не умереть от гипертонии

^{‹‹1››.} Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.

^{‹‹2››.} Das P, Samarasekera U. The story of GBD 2010: a «super-human» eff ort. Lancet. 2012; 380 (9859):2067–70.

^{‹‹3››.} Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.

^{‹‹4››.} Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.

^{‹‹5››.} Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.

^{‹‹6››.} Bromfield S, Muntner P. High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs. Curr Hypertens Rep. 2013;15(3):134–6.

^{‹‹7››.} Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.

^{‹‹8››.} American Heart Association. Understanding Blood Pressure Readings. http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/Understanding-Blood-Pressure-Readings_ UCM_301764_Article.jsp. March 11, 2015. Accessed March 11, 2015.

^{‹‹9››.} Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol. 2014;63(12): 1230–8.

^{‹‹10››.} Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012. NCHS Data Brief. 2013;(133):1–8.

^{‹‹11››.} Walker AR, Walker BF. High high-density-lipoprotein cholesterol in African children and adults in a population free of coronary heart diseae. Br Med J. 1978;2(6148):1336–7.

^{‹‹12››.} Donnison CP. Blood pressure in the African native. Lancet. 1929;213(5497):6–7.

^{‹‹13››.} Macmahon S, Neal B, Rodgers A. Hypertension— time to move on. Lancet. 2005;365(9464): 1108–9.

^{‹‹14››.} Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

^{‹‹15››.} Donnison CP. Blood pressure in the African native. Lancet. 1929;213(5497):6–7.